Lacto-N-fucopentaose I (LNFP I) is one of the most structurally complex and biologically significant fucosylated Human Milk Oligosaccharide (HMO). As a pentasaccharide containing a ɑ-1,2-fucosyl linkage at the non-reducing end of the Lacto-N-tetraose (LNT) backbone, LNFP I is a major component of milk from "Secretor" mothers. It plays a critical role in neonatal health by acting as a decoy receptor for pathogens, stimulating the growth of beneficial gut microbiota, and modulating the infant's immune response. CD BioGlyco offers a specialized LNFP I production service powered by Synthetic Glycobiology. By engineering advanced microbial cell factories, we overcome the traditional barriers of low natural abundance and high chemical synthesis costs, providing high-purity LNFP I for global research and commercial applications.
Core Technologies
CD BioGlyco utilizes a multi-dimensional engineering approach to achieve high-efficiency LNFP I biosynthesis:
Engineered α-1,2-Fucosyltransferase Modules
We employ highly specific ɑ-1,2-fucosyltransferases (such as futC or WbgL) that are codon-optimized for high-level expression in our microbial hosts, ensuring the precise decoration of the LNT backbone.
GDP-L-fucose Pathway Enhancement
Our platform optimizes the de novo GDP-L-fucose biosynthetic pathway by overexpressing key enzymes, including Gmd and WcaG, while simultaneously regulating metabolic flux to minimize byproduct formation.
Backbone Precursor Optimization
To ensure a steady supply of the tetrasaccharide core, we integrate high-efficiency β-1,3-galactosyltransferase and β-1,3-N-acetylglucosaminyltransferase modules to sustain LNT levels for downstream fucosylation.
Markerless Genomic Integration
We utilize CRISPR-mediated chromosomal integration to create stable, plasmid-free production strains, eliminating the need for antibiotics and enhancing the industrial robustness of the fermentation process.
Defining the Future of Neonatal Nutrition through Complex Glycan Engineering.
At CD BioGlyco, our LNFP I production service is designed to be the definitive solution for the high-yield synthesis of complex fucosylated HMOs. Our service scope extends far beyond basic manufacturing; we provide a full-spectrum partnership that begins with custom strain development, where our scientists refactor microbial metabolism to suit your specific scale-up requirements. We recognize that LNFP I is a high-value ingredient that requires meticulous attention to detail, which is why our process engineering team focuses on maximizing the conversion rate of lactose to the final pentasaccharide.
Our expertise covers the synthesis of LNFP I as a standalone high-purity ingredient or as part of a human-identical HMO Blend. We offer specialized sub-page entry options for clients interested in co-producing LNFP I with 2'-FL to better simulate the natural profile of human breast milk. Furthermore, our scope includes stability testing and formulation support, ensuring that our LNFP I maintains its structural integrity in various matrices, from infant formula to dietary supplements. We are committed to providing the technical infrastructure and scientific rigor required to bring these complex glycans to the global market effectively.
Workflow
1. Pathway Modeling & Strain Construction
We begin with the computational design of a complete biosynthetic pathway for LNFP I. This involves constructing synthetic operons that co-express the necessary genes: those for the LNT backbone (involving specific galactosyltransferases and an N-acetylglucosaminyltransferase) and the α-1,2-fucosyltransferase (e.g., FutC) that adds the terminal fucose. Prior to physical construction, we employ genome-scale metabolic modeling and flux balance analysis (FBA) to simulate carbon and energy flow through the host's native metabolism integrated with this new pathway. This in silico analysis predicts and identifies potential bottlenecks, particularly in the supply of critical nucleotide-sugar precursors like GDP-L-fucose and UDP-GlcNAc. Based on these insights, we proactively engineer the production host, often an optimized E. coli strain, by upregulating precursor biosynthesis genes and/or knocking out competing pathways to ensure efficient precursor channeling into LNFP I synthesis.
2. Iterative Module Reprogramming
The biosynthetic pathway is treated as distinct, tunable genetic modules. We employ an iterative design-build-test-learn (DBTL) cycle to optimize the entire system. Using libraries of genetic parts with varying strengths (e.g., constitutive or inducible promoters, ribosomal binding sites), we systematically adjust the relative expression levels of the fucosyltransferase gene versus the suite of genes responsible for the LNT backbone assembly. The primary objective is to achieve a perfectly balanced enzyme stoichiometry that ensures the LNT intermediate is fucosylated as rapidly as it is synthesized. This precise reprogramming prevents the accumulation of unfucosylated intermediates like LNT or misfucosylated byproducts like LNFP II, thereby maximizing the molar yield of the target LNFP I.
3. High-Performance Fermentation
Production is scaled in precision-controlled, stirred-tank bioreactors using an advanced fed-batch fermentation strategy. We utilize sophisticated process control systems to continuously monitor and adjust critical parameters in real-time. This includes maintaining the optimal pH and temperature for both cell growth and glycosyltransferase activity, as well as dynamically controlling the feeding rates of key carbon sources (e.g., glycerol) and acceptor/donor precursors (lactose, fucose source). By decoupling growth from production phases and carefully managing metabolic loads, we achieve high cell densities while sustaining a prolonged, high-yield production phase. This optimized process consistently achieves LNFP I titers that meet and exceed the highest benchmarks reported in scientific literature and patent data.
4. Multi-Stage Purification
Recovering high-purity LNFP I involves a sequential, scalable downstream process. The harvest broth is first clarified via continuous centrifugation or tangential flow microfiltration to remove biomass. The clarified solution undergoes nanofiltration, a membrane process that concentrates the product and removes low-molecular-weight impurities, salts, and media components. The final and most critical step is industrial-scale chromatography, typically using specialized resins in a simulated moving bed (SMB) or batch column configuration. This chromatographic step is designed for high-resolution separation, effectively isolating LNFP I from closely related residual sugars (e.g., lactose, LNT) and nucleotide-sugar precursors, resulting in a product with a chemical purity exceeding 98%.
5. Quality Assurance & Structural Profiling
Each production batch is subjected to a rigorous, multi-tiered analytical release protocol. High-performance liquid chromatography-tandem mass spectrometry (LC-MS/MS) provides precise quantification, confirms the exact molecular mass, and screens for any residual impurities or isomeric contaminants. Definitive structural verification is achieved through two-dimensional proton nuclear magnetic resonance (2D 1H-NMR) spectroscopy. This technique conclusively confirms the exact pentasaccharide sequence and, most critically, the presence and anomeric configuration of the α-1,2 linkage between the terminal fucose and the galactose residue. This comprehensive profiling ensures the final product is structurally identical to the LNFP I found in human milk, guaranteeing its biological authenticity.
Publication Data
Journal: EFSA Journal
DOI: 10.2903/j.efsa.2023.8412
IF: 3.3
Published: 2023
Results: The European Food Safety Authority (EFSA) Panel on Nutrition, Novel Foods and Food Allergens (NDA) conducted a comprehensive safety assessment of a novel food (NF) consisting of a mixture of LNFP-I and 2'-fucosyllactose (2'-FL), which are HMOs naturally present in human milk. The NF is produced by microbial fermentation using a genetically modified strain of E. coli K-12 DH1. The evaluation covered the NF's identity, production process, compositional data, stability, specifications, history of use, proposed uses and intake levels, absorption, distribution, metabolism, and excretion (ADME), nutritional information, and toxicological studies, including genotoxicity and a 90-day subchronic toxicity study in neonatal rats. The Panel concluded that the NF is safe under the proposed conditions of use, such as in infant formula, follow-on formula, food supplements, and other food categories, for the general population, as the anticipated intake does not exceed natural exposure levels in breastfed infants and no adverse effects were observed in toxicological tests.
Application
Anti-Infective Therapeutics
Used in the development of glycan-based agents that block the adhesion of enteric and respiratory pathogens to human cell surfaces.
Microbiome Modulation
LNFP I selectively promotes the growth of specific Bifidobacterium species, supporting the establishment of a healthy neonatal gut environment.
Immune System Education
Research demonstrates that LNFP I plays a role in priming the innate immune system and reducing the risk of inflammatory responses.
Necrotizing Enterocolitis (NEC) Research
LNFP I is studied for its protective effects on the intestinal barrier, potentially reducing the incidence of NEC in preterm infants.
Advantages
Exceptional Regioselectivity
We utilize specialized ɑ-1,2-fucosyltransferases that ensure the precise decoration of the LNT core, eliminating the risk of mis-linked isomers.
Sustainable Bio-Synthesis
Our fermentation-based approach is environmentally superior to traditional chemical synthesis, utilizing renewable carbon sources and minimizing chemical waste.
Biologically Identical Structure
LNFP I is chemically and biologically indistinguishable from the glycan found in human milk, ensuring maximum efficacy in pre-clinical studies.
Low Impurity Profiles
Our refined purification protocols reduce residual lactose, LNT, and fucosylated intermediates to near-undetectable levels, ensuring a >98% pure product.
Frequently Asked Questions
Customer Review
"CD BioGlyco provided the only LNFP I on the market with the structural purity required for our pathogen-binding study. Exceptional quality."
– Dr. A.W., Senior Research Fellow, Nutrition Science
"The scalability of CD BioGlyco's platform is impressive. We successfully transitioned from lab-scale tests to a full pilot run without any loss in LNFP I yield."
– Manager T.K., Product Development
"Having access to highly characterized, human-identical LNFP I has been a game-changer for our neonatal microbiome project. Their NMR data is definitive."
– Dr. L.C., Head of Clinical Research
"The documentation provided by CD BioGlyco was incredibly thorough, making our safety assessment process for the new formula much smoother."
– Director J.M., Regulatory Affairs
"CD BioGlyco's expertise in fucosyltransferase engineering is evident. Their LNFP I shows zero contamination with Type II isomers, which is critical for our work."
– Dr. R.S., Principal Scientist, Glycobiology
Associated Services
Galα1,3Galβ1,4Glc Production
Production of the α-Gal epitope trisaccharide for immunological and xenotransplantation research.
GlcNAcβ1,3Galβ1,4Glc Production
Synthesis of the Lacto-N-triose II (LNT II) backbone precursor with high purity.
Galα1,3LacN3 Production
Specialized synthesis of rare glycans for diagnostic and therapeutic development.
CD BioGlyco is at the forefront of the synthetic glycobiology revolution, providing a robust and reliable LNFP I production service. By combining advanced metabolic engineering with industrial-scale fermentation, we deliver complex, human-identical milk oligosaccharides that meet the highest standards of purity and structural accuracy. To learn more about our LNFP I production capabilities or to discuss a custom project with our biology specialists, please contact us today.
Reference
EFSA Panel on Nutrition.; et al. Safety of lacto-N-fucopentaose I/2'-fucosyllactose (LNFP-I/2'-FL) mixture as a novel food pursuant to Regulation (EU) 2015/2283. EFSA Journal. 2023, 21(12): e8412. (Open Access)
For research use only. Not intended for any clinical use.
